Top 20 global pharma brand in 2012 ims health midas 2012

3,549 views

Published on

Top 20 Global Pharma Brands in 2012 as per IMS Health

Published in: Business, Health & Medicine
0 Comments
5 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
3,549
On SlideShare
0
From Embeds
0
Number of Embeds
6
Actions
Shares
0
Downloads
85
Comments
0
Likes
5
Embeds 0
No embeds

No notes for slide

Top 20 global pharma brand in 2012 ims health midas 2012

  1. 1. Top 20 Global Pharma Brandin 2012(IMS Health MIDAS 2012)Presented ByMasum ChowdhuryManager, SBMDAsiatic Laboratories Ltd.
  2. 2. Global Rank 1 Brand 2012Market Size: 8.9 Billion US$Growth: 1.7%Generic:Fluticasone propionate/Salmeterol xinafoateMajor Indication:Asthma
  3. 3. Global Rank 2 Brand 2012Market Size: 8.5 Billion US$Growth: 18.5%Generic:AdalimumabMajor Indication:Rheumatoid Arthritis
  4. 4. Global Rank 3 Brand 2012Market Size: 8.3 Billion US$Growth: 3.0%Generic:RosuvastatinMajor Indication:Lipid Lowering Agent
  5. 5. Global Rank 4 Brand 2012Market Size: 7.5 Billion US$Growth: (7.2%)Generic:EsomeprazoleMajor Indication:Peptic Ulcer
  6. 6. Global Rank 5 Brand 2012Market Size: 7.5 Billion US$Growth: 9.7%Generic:EtanerceptMajor Indication:Rheumatoid Arthritis,Ankylosing Spondylitis
  7. 7. Global Rank 6 Brand 2012Market Size: 7.3 Billion US$Growth: 10.6%Generic:InflikimabMajor Indication:Rheumatoid Arthritis,Ankylosing SpondylitisUlcerative Colitis
  8. 8. Global Rank 7 Brand 2012Market Size: 7.0 Billion US$Growth: 11.5%Generic:AripiprazoleMajor Indication:DepressionBipolar disorderSchizophrenia.
  9. 9. Global Rank 8 Brand 2012Market Size: 6.6 Billion US$Growth: 19.3%Generic:Insulin glargine 100 iu/mlMajor Indication:Type 1 diabetes mellitus (Children)Type 2 diabetes mellitus (Adults)
  10. 10. Global Rank 9 Brand 2012Market Size: 6.0 Billion US$Growth: 8.8%Generic:RituximabMajor Indication:non-Hodgkin’s lymphoma
  11. 11. Global Rank 10 Brand 2012Market Size: 5.8 Billion US$Growth: 23.2%Generic:DuloxetineMajor Indication:Major Depressive Disorder
  12. 12. Global Rank 11 Brand 2012Market Size: 5.4 Billion US$Growth: 4.5%Generic:BevacizumabMajor Indication:Metastatic colorectal cancer (colon cancer),Non–small cell lung cancerGlioblastoma
  13. 13. Global Rank 12 Brand 2012Market Size: 5.2 Billion US$Growth: (44.9%)Generic:ClopidogrelMajor Indication:Recent MI,Recent Stroke
  14. 14. Global Rank 13 Brand 2012Market Size: 5.1 Billion US$Growth: 9.9%Generic:Tiotropium BromideMajor Indication:Bronchospasm in people withbronchitis, emphysema, or COPD
  15. 15. Global Rank 14 Brand 2012Market Size: 5.1 Billion US$Growth: (60.7)Generic:AtorvastatinMajor Indication:Lipid lowering Agent
  16. 16. Global Rank 15 Brand 2012Market Size: 5.0 Billion US$Growth: 9.0%Generic:TrastuzumabMajor Indication:Breast Cancer
  17. 17. Global Rank 16 Brand 2012Market Size: 4.7 Billion US$Growth: (25.2%)Generic:MontelukastMajor Indication:Asthmatic Inflammation
  18. 18. Global Rank 17 Brand 2012Market Size: 4.6 Billion US$Growth: 13.9%Generic:PregabalinMajor Indication:Diabetic NeuropathyNeuropathic Pain
  19. 19. Global Rank 18 Brand 2012Market Size: 4.5 Billion US$Growth: 11.4%Generic:Glatiramer AcetateMajor Indication:Relapsing-Remitting MultipleSclerosis
  20. 20. Global Rank 19 Brand 2012Market Size: 4.3 Billion US$Growth: 3.8%Generic:ImatinibMajor Indication:Acute Lymphoblastic LeukemiaHypereosinophilicSyndrome/Eosinophilic Leukemia
  21. 21. Global Rank 20 Brand 2012Market Size: 4.3 Billion US$Growth: 2.1%Generic:PegfilgrastymMajor Indication:Febrile neutropenia
  22. 22. Thanks
  23. 23. Prepared ByMasum ChowdhuryManager,Strategic Brand Management DepartmentAsiatic Laboratories Ltd.masum.pha@gmail.com,+880-0171-7642874, +880-0193 7990014

×